Angiogenin and SDF-1α serum concentration in patients with systemic sclerosis in relation to clinical status by Dziankowska-Bartkowiak, Bożena et al.
Angiogenin and SDF-1ʱ serum concentration in patients
with systemic sclerosis in relation to clinical status
Bożena Dziankowska-Bartkowiak, Zofia Gerlicz-Kowalczuk, Elżbieta Waszczykowska
Abstract
I In nt tr ro od du uc ct ti io on n: :    Systemic  sclerosis  (SSc)  is  a connective  tissue  disorder
characterized by tissue hypoxia due to vascular changes and excessive fibrosis
of the skin and internal organs. Damage to blood vessels and endothelium, as
well as imbalance of vascular homeostasis, impairment of angiogenesis and
vasculogenesis are observed in the course of the disease. The aim of the study
was to investigate the pro-angiogenic factors angiogenin and SDF-1ʱ in patients
with SSc.
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s: :   Serum samples were collected from 50 patients with
dSSc (diffuse SSc) and lSSc (limited SSc) and from 38 patients used as a healthy
control group. We explored: 1) how the serum concentrations of SDF-1ʱ and
angiogenin  differ  in  the  investigated  groups;  2)  the  correlation  among
chemokines in SSc and the duration of the disease, Raynaud’s phenomenon,
sclerosis of the skin and TSS (total skin score). 
R Re es su ul lt ts s: :   Patients with SSc showed statistically significantly higher serum
angiogenin concentration and there was no correlation between duration of the
disease and Raynaud’s phenomenon, skin sclerosis or TSS. There was also no
difference or no correlation between serum level of SDF-1ʱ and the investigated
groups.
C Co on nc cl lu us si io on ns s: :   The increase in angiogenin concentration in the serum in patients
with SSc may confirm endothelial damage caused by hypoxia and reduced
vascular  perfusion  due  to  the  course  of  SSc  without  contributing  to
compensatory revascularization.
K Ke ey y   w wo or rd ds s: :   systemic sclerosis, angiogenesis, vasculogenesis, angiogenin, SDF-1ʱ.
Introduction
Systemic sclerosis (SSc) is an autoimmune disease in which the
following characteristics are observed: vascular changes, sclerosis of the
skin and of internal organs. The spectrum of vascular abnormalities
extends from sclerosis of the skin to fibrosis of all organs. 
It was proven that tissue hypoxia aggravates with the course of the
disease due to reduced blood flow and that it induces formation of new
blood vessels from the already existing ones (angiogenesis) or from
endothelial progenitor cells (EPC) from the bone marrow (vasculogenesis)
that circulate in the blood. Survival of tissue destroyed by the vascular
autoimmune process is strictly dependent on angiogenesis. There are many
factors, such as: modelling the angiogenesis process and formation of new
capillaries stimulated by hypoxia, the inflammatory process and pro-
angiogenic factors, such as vascular endothelial growth factor (VEGF) [1].
C Co or rr re es sp po on nd di in ng g   a au ut th ho or r: :
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The  literature  on  the  subject  confirms  that
regeneration of impaired vessels in the process of
autoaggression depends on angiogenesis and also
on vasculogenesis [2].
In the course of systemic sclerosis, a decreased
number of EPC was described, related to the
clinical stage of the disease and found to be
directly proportional to the course of the disease
[2]. EPC are released by the bone marrow and
may play a vital role in formation of new vessels.
Stromal cell-derived factor-alpha 1 (SDF-1ʱ) and
VEGF mediate the endothelial progenitor cells’
mobilization and differentiation and have a strong
influence on regulation of chemotaxis of the
CXCR4 (chemokine [C-X-C] receptor 4)-expressing
cell population [3]. Interestingly, it was observed
that  SDF-1ʱ acts  locally  within  the  hypoxic
environment and stimulates direct differentiation
of  the  recruited  bone  marrow  cells  into
endothelial cells [4, 5]. Moreover, it was proved
that SDF-1 and CXCR4 were up-regulated in the
skin of patients with early (oedematous) SSc,
both in the diffuse and limited cutaneous forms,
and  they  progressively  decreased  with  the
duration of the disease [6].
Although  the  pathogenesis  of  SSc  is  not
completely  understood,  it  is  known  that  both
vasculogenesis and angiogenesis are impaired.
Angiogenin  is  one  of  the  most  potent  pro-
angiogenic factors and regulates vessel growth and
plays a vital role in the process of angiogenesis 
and cell proliferation. The protein, exerting its
ribonucleic activity, stimulates basement membrane
degradation, endothelial cell penetration, migration
and  formation  of  tubular  vascular  structures.
However, the angiogenin receptor is not known 
yet [7-9].
The present study was designed to widen and
deepen the problem of angiogenesis disturbing
factors in SSc, which might contribute to a better
understanding  of  vascular  abnormalities.  We
hypothesized that the cause of vascular abnor  -
malities in patients with SSc might be correlated
with the serum concentration of angiogenin and
SDF-1ʱ, which may have a prognostic implication
for the duration and severity of the disease.
Material and methods
Forty-five females and 5 males with SSc (41 lSSc,
9 dSSc) were recruited from the Department of
Dermatology and Venereology, Medical University
of Lodz. The onset of the disease ranged from 1 to
30 years ago (mean 9 years) and was defined as
the time at which skin involvement occurred. The
mean age was 53 years (range from 20 to 77 years).
The medical history and clinical examination were
taken  and,  if  necessary,  additional  tests  were
performed (Table I). All patients met the American
College of Rheumatology criteria for the classifi  -
cation of SSc [10]. The severity of the disease was
assessed according to international guidelines [1].
We measured the TSS (total skin score) according
to Kahaleh’s score [12]. At the time of serum
collection  for  testing,  all  patients  with  SSc 
were taking vasodilator drugs and corticosteroids
(9 patients, 5 with dSSc), methotrexate (2 patients,
1 with dSSc) and cyclophosphamide (2 patients, 
1 with dSSc).
Systemic sclerosis patients were compared with
the control subjects of the same sex and similar age
with no systemic diseases or medication. Blood
samples from the patients and the control subjects
were collected from 8:00 to 9:00 am after overnight
fasting. All samples were collected into trisodium-
citrated tubes and sera of all subjects were extracted
from the blood samples after centri  fugation at
2800 g for 10 min and stored at –20ﾰC until use.
In our study we used the SDF-1ʱ Immunoassay
(R&D Systems, Abingdon, Oxon, UK) and Human
Angiogenin Immunoassay (R&D Systems, Abingdon,
Oxon,  UK)  based  on  quantitative  colorimetric
sandwich ELISA tests, according to the manu  -
facturer’s instructions. 
We investigated the levels of the angiogenin and
SDF-1ʱ concentration in the serum and their cor  -
relation  with  the  duration  of  Raynaud’s  phe  -
nomenon, skin sclerosis and TSS.
Statistical significance was analysed by non-
parametric Mann-Whitney test, Student’s t-test and
Spearman’s rank correlation test. P values less than
0.05 were considered significant.
The study was approved by the Ethical Com  -
mittee of the Medical University of Lodz.
A Ag ge e S Se ex x R Re ey yn no ou ud d   p ph h S Sc cl le er ro os si is s T TS SS S
M Mi in n. . M Ma ax x. . M Me ea an n F F M M l lS SS Sc c d dS SS Sc c M Mi in n. . M Ma ax x. . M Me ea an n M Mi in n. . M Ma ax x. . M Me ea an n M Mi in n. . M Ma ax x. . M Me ea an n
SSc ANG 38 77 54 45 5 41 91 30 91 20 74 40 15
SDF-1ʱ 20 70 52 24 1 18 71 30 9115 64 32 15
Control ANG 34 68 50 21 4 00000000000
SDF-1ʱ 21 68 49 16 1 00000000000
SSc – systemic sclerosis group, Control – control group, Reynould ph – Reynoud phenomenon duration, Sclerosis – sclerosis duration, TSS – Total
Skin Score, F – female, M – male, lSSc – limited SSc, dSSc – diffuse SSc
T Ta ab bl le e   I I. .   Clinical characteristic of the patients
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Results
A An ng gi io og ge en ni in n
In the investigated groups, higher concentrations
of angiogenin in serum were found in SSc patients
compared with the control subjects (323.62 ng/ml
vs. 255.31 ng/ml; SD 90.39 vs. 39.48). The differences
were statistically significant (p = 0.000082) (Table II). 
There was no statistically significant difference
between the patients with lSSc or dSSc taking or
not taking immunosuppressive drugs (Tables III 
and IV).
The differences between serum concentration
were not significant (p = 0.974667) among the
investigated groups – lSSc and dSSc. There was no
correlation  with  the  duration  of  Raynaud’s
phenomenon, skin sclerosis or TSS (Table V).
S SD DF F- -1 1ʱ ʱ
There was no statistical difference in SDF-1ʱ
serum  concentration  among  the  investigated
groups (Table I).
There was no statistically significant difference
between  the  patients  with  lSSc  or  dSSc  and
whether or not they took immunosuppressive drugs
(Tables IV and V).
Although no statistically significant difference 
or correlation between serum concentration of 
SDF-1ʱ in the investigated parameters was found,
S Se er ru um m   c co on nc ce en nt tr ra at ti io on n   [ [n ng g/ /m ml l] ]
A An ng gi io og ge en ni in n S SD DF F- -1 1ʱ ʱ
n n M Me ea an n M Me ed di ia an n M Mi in n. . M Ma ax x. . S SD D n n M Me ea an n M Me ed di ia an n M Mi in n. . M Ma ax x. . S SD D
lSSc 35 322.48 329 28 551 96.05 17 2.594 2.601 2.015 3.675 0.411
dSSc 10 327.60 310 255 495 71.22 7 2.653 2.597 2.223 3.473 0.418
Control 25 255.31 249 177 336 39.48 16 2.746 2.662 2.084 3.954 0.442
Angiogenin: lSSc-dSSc: p = 0.978219; lSSc-Control: p = 0.000684; dSSc-Control: p = 0.001230
SDF-1ʱ: lSSc-dSSc: p = 0.974667; lSSc-Control: p = 0.249042; dSSc-Control: p = 0.639997
n – number of patients, SSc – systemic sclerosis group, Control – control group, SD – standard deviation
T Ta ab bl le e   I II I. .   Serum concentration of angiogenin and SDF-1ʱ among SSc and control groups
S Se er ru um m   c co on nc ce en nt tr ra at ti io on n   [ [n ng g/ /m ml l] ]   o of f   a an ng gi io og ge en ni in n   a an nd d   S SD DF F- -1 1ʱ ʱ b be et tw we ee en n   l lS SS Sc c   t ta ak ki in ng g   i im mm mu un no os su up pp pr re es ss si iv ve e   d dr ru ug gs s
n n M Me ea an n M Me ed di ia an n M Mi in n. . M Ma ax x. . S SD D
Angiogenin  7 270.52 276.44 28.80 390.60 119.17
SDF-1ʱ 5 2.67 2.72 2.26 2.90 0.26
S Se er ru um m   c co on nc ce en nt tr ra at ti io on n   [ [n ng g/ /m ml l] ]   o of f   a an ng gi io og ge en ni in n   a an nd d   S SD DF F- -1 1ʱ ʱ b be et tw we ee en n   l lS SS Sc c   
a an nd d   c co on nt tr ro ol l   g gr ro ou up ps s   n no ot t   t ta ak ki in ng g   i im mm mu un no os su up pp pr re es ss si iv ve e   d dr ru ug gs s
Angiogenin  28 33.54 340.00 216.60 551.00 87.10
SDF-1ʱ 12 2.56 2.44 2.01 3.67 0.44
T Ta ab bl le e   I II II I. .   Comparison of serum concentration of angiogenin (p = 0.386449) and SDF-1ʱ (p = 0.342789) between lSSc
patients with/without immunosuppresive therapy
S Se er ru um m   c co on nc ce en nt tr ra at ti io on n   [ [n ng g/ /m ml l] ]   o of f   a an ng gi io og ge en ni in n   a an nd d   S SD DF F- -1 1ʱ b be et tw we ee en n   d dS SS Sc c   t ta ak ki in ng g   i im mm mu un no os su up pp pr re es ss si iv ve e   d dr ru ug gs s
n n M Me ea an n M Me ed di ia an n M Mi in n. . M Ma ax x. . S SD D
Angiogenin  6 325.10 30.60 255.80 495.00 88.27
SDF-1ʱ 4 2.81 2.62 2.51 3.47 0.44
S Se er ru um m   c co on nc ce en nt tr ra at ti io on n   [ [n ng g/ /m ml l] ]   o of f   a an ng gi io og ge en ni in n   a an nd d   S SD DF F- -1 1ʱ ʱ b be et tw we ee en n   d dS SS Sc c   
a an nd d   c co on nt tr ro ol l   g gr ro ou up ps s   n no ot t   t ta ak ki in ng g   i im mm mu un no os su up pp pr re es ss si iv ve e   d dr ru ug gs s
Angiogenin  4 331.35 321.40 287.60 395.00 46.90
SDF-1ʱ 3 2.44 2.27 2.22 2.83 0.33
T Ta ab bl le e   I IV V. .   Comparison of serum concentration of angiogenin (p = 0.522436) and SDF-1ʱ (p = 0.288852) between dSSc
patients with/without immunosuppresive therapy 
Bożena Dziankowska-Bartkowiak, Zofia Gerlicz-Kowalczuk, Elżbieta WaszczykowskaArch Med Sci 1, February / 2011 95
we observed a tendency for a negative correlation
between the serum level of SDF-1ʱ and the duration
of Raynaud’s phenomenon (ˁ = –0.270) and skin
sclerosis (ˁ = –0.388) (Table II). Similarly, we observed
a tendency for a negative Spearman’s correlation
coefficient between SDF-1ʱ serum concentration and
duration of the disease. However, these results were
not statistically significant (p > 0.05).
Discussion
It seems that in the pathogenesis of systemic
sclerosis neovasculogenesis, impairment is a vital
element  in  the  development  of  the  disease.
According to the literature on the subject, both 
an  increase  and  a decrease  in  angio-  and
vasculogenesis may be a manifestation of the
disease [13, 14].
This study confirms the hypothesis of deep
impairment of angiogenesis in SSc. It is the first
study demonstrating elevated angiogenin concen  -
tration in SSc patient serum compared with healthy
subjects. Increased release of angiogenin may be
indicative of compensatory ineffective angiogenesis
in  these  patients  which  was  not  observed  in
revascularization of the healthy population. 
It may also suggest that the process, which is
dependent on this molecule, might not be impaired
due to the course of SSc, but we hypothesized that
the elevated level of angiogenin may occur due to
the impairment of endothelial cell differentiation
described by Cipriani [15], which showed decreased
capacity of specific endothelial activities occurring
in angiogenesis. A large decrease in the level of
angiogenin reduces the capacity to induce tumour
growth and angiogenesis, even in the presence of
elevated bFGR (basic fibroblast growth factor) and
VEGF [16]. 
Interestingly, the literature describes elevated
angiogenin serum level in chronic heart failure [17],
which is related to worsening of heart failure
severity. Tello-Montoliu [18] described increased
plasma  angiogenin  level  in  acute  coronary
syndromes with predictive adverse events during
the follow-up and correlated this protease with the
destabilization of atherosclerotic plaque.
In addition to defective angiogenesis, vasculo  -
genesis is also impaired in SSc. Reduced numbers
and functional defects of endothelial progenitor
cells are observed despite increased endothelial cell
activation markers [19, 20]. 
Considering the insufficient vasculogenesis in
SSc patients, up-regulation in SDF-1ʱ level could
be expected, which could have a positive effect on
the described lower number of EPC in patients with
systemic sclerosis [2, 15]. SDF-1ʱ takes part in the
promotion of recruitment, growth and survival of
cells from the bone marrow stromal stem cells [21].
Their  participation  in  tissue  regeneration  in
ischaemic cardiomyopathy is well described. 
Surprisingly, we did not observe any statistical
significance comparing serum concentration of 
SDF-1ʱ in the SSc and healthy control groups. This
may suggest that either the homeostasis between
SDF-1ʱ and CXCR4 is maintained or the hypo  -
thetical decreased level of CXCR4 [22, 23] does not
influence the increased level of SDF-1ʱ in the serum
in  our  patients.  In  our  studies  we  observed
a tendency for a negative Spearman’s correlation
coefficient, which might indicate that investigation
of a larger group of patients could be positive and
it  also  means  that  the  level  of  SDF-1ʱ would
decrease with the course of the disease. Interes  -
tingly, cell recruitment from bone marrow might
even be within normal limits. Furthermore, Cipriani
reported a significantly lower expression of CXCR4
in SSc mesenchymal stem cells, thus lowering 
their differentiation into endothelial cells. Under  -
expression  of  CXCR4  may  correlate  with  the
duration of SSc by contrast with overexpression,
which supports tumour growth and would stimulate
excessive angiogenesis [24]. Moreover, Cipriani
observed SDF-1ʱ and CXCR4 up-regulation in the
skin of patients with early SSc, dSSc and lSSc, and
also progressive reduction of these molecules with
the course of the disease, which our study also
suggests. The difference between our observations,
where the level of SDF-1ʱ in SSc patient serum is
the  same  as  in  the  control  subjects,  and  the
observations  described  in  the  literature  on 
up-regulation of SDF-1ʱ in the skin of SSc patients,
may  indicate  only  local  impairment  of  the 
SDF-1ʱ/CXCR4 axis [25].
To summarize, a high level of pro-angiogenic
factors  may  indicate  disturbances  in  revas  -
cularization homeostasis. Patients with SSc show
increased  serum  concentration  of  many  pro-
angiogenic factors including angiogenin, as was
shown  for  the  first  time  in  our  study,  to
hypothetically  reconstruct  blood  vessels  and
increase  tissue  blood  perfusion  stimulated  by
hypoxia. 
R Ra ay yn no ou ud d   p ph h S Sk ki in n   s sc cl le er ro os si is s T TS SS S
Angiogenin ˁ 0.127 0.096 0.078
p > 0.05 > 0.05 > 0.05
SDF-1ʱˁ –0.270 –0.388 0.058
p > 0.05 > 0.05 > 0.05
T Ta ab bl le e   V V. . Correlation among angiognenin and SDF-1ʱ
serum concentration and the duration of Raynould
phenomenon, skin sclerosis and TSS
Reynould ph – Reynoud phenomenon duration, skin sclerosis – skin
sclerosis duration, TSS – Total Skin Score
ˁ – Spearman's rank correlation coefficient, p > 0.05 – no statistical
significant
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